Griffiths WA. Pityriasis rubra pilaris. Clin Exp Dermatol. 1980 Mar. 5(1):105-12. [QxMD MEDLINE Link].
Griffiths WA. Pityriasis rubra pilaris: the problem of its classification. J Am Acad Dermatol. 1992 Jan. 26(1):140-2. [QxMD MEDLINE Link].
Auffret N, Quint L, Domart P, Dubertret L, Lecam JY, Binet O. Pityriasis rubra pilaris in a patient with human immunodeficiency virus infection. J Am Acad Dermatol. 1992 Aug. 27(2 Pt 1):260-1. [QxMD MEDLINE Link].
Blauvelt A, Nahass GT, Pardo RJ, Kerdel FA. Pityriasis rubra pilaris and HIV infection. J Am Acad Dermatol. 1991 May. 24(5 Pt 1):703-5. [QxMD MEDLINE Link].
Martin AG, Weaver CC, Cockerell CJ, Berger TG. Pityriasis rubra pilaris in the setting of HIV infection: clinical behaviour and association with explosive cystic acne. Br J Dermatol. 1992 Jun. 126(6):617-20. [QxMD MEDLINE Link].
Miralles ES, Nunez M, De Las Heras ME, Perez B, Moreno R, Ledo A. Pityriasis rubra pilaris and human immunodeficiency virus infection. Br J Dermatol. 1995 Dec. 133(6):990-3. [QxMD MEDLINE Link].
Kurzydlo AM, Gillespie R. Paraneoplastic pityriasis rubra pilaris in association with bronchogenic carcinoma. Australas J Dermatol. 2004 May. 45(2):130-2. [QxMD MEDLINE Link].
Remedios IM, Jensen JD, Beckum K, McKay K, Kissel R. Paraneoplastic pityriasis rubra pilaris as the presenting manifestation of metastatic squamous cell carcinoma. J Drugs Dermatol. 2014 May. 13(5):610-2. [QxMD MEDLINE Link].
Howe K, Foresman P, Griffin T, Johnson W. Pityriasis rubra pilaris with acantholysis. J Cutan Pathol. 1996 Jun. 23(3):270-4. [QxMD MEDLINE Link].
Fuchs-Telem D, Sarig O, van Steensel MA, et al. Familial Pityriasis Rubra Pilaris Is Caused by Mutations in CARD14. Am J Hum Genet. 2012 Jul 13. 91(1):163-70.
Takeichi T, Sugiura K, Nomura T, Sakamoto T, Ogawa Y, Oiso N, et al. Pityriasis Rubra Pilaris Type V as an Autoinflammatory Disease by CARD14 Mutations. JAMA Dermatol. 2017 Jan 1. 153 (1):66-70. [QxMD MEDLINE Link].
Vanderhooft SL, Francis JS, Holbrook KA, Dale BA, Fleckman P. Familial pityriasis rubra pilaris. Arch Dermatol. 1995 Apr. 131(4):448-53. [QxMD MEDLINE Link].
Mohrenschlager M, Abeck D. Further clinical evidence for involvement of bacterial superantigens in juvenile pityriasis rubra pilaris (PRP): report of two new cases. Pediatr Dermatol. 2002 Nov-Dec. 19(6):569. [QxMD MEDLINE Link].
Allison DS, El-Azhary RA, Calobrisi SD, Dicken CH. Pityriasis rubra pilaris in children. J Am Acad Dermatol. 2002 Sep. 47(3):386-9. [QxMD MEDLINE Link].
Mohamed M, Belhadjali H, Hammedi F, Meriem CB, Zili J. Pityriasis rubra pilaris occurring after vaccination with diphtheria-pertussis-tetanus and oral poliovirus vaccines. Indian J Dermatol Venereol Leprol. 2015 Nov-Dec. 81 (6):618-20. [QxMD MEDLINE Link].
Martinez Calixto LE, Suresh L, Matsumura E, Aguirre A, Radfar L. Oral pityriasis rubra pilaris. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 May. 101(5):604-7. [QxMD MEDLINE Link].
Abbott RA, Griffiths WA. Pityriasis rubra pilaris type 1 spontaneously resolving after 20 years. Clin Exper Dermatol. 2009. 34:378-379.
Martín Callizo C, Molinero Caturla J, Sánchez Sánchez J, Penín Mosquera RM. Scarring Alopecia in Classic Adult Type I Pityriasis Rubra Pilaris. Actas Dermosifiliogr. 2014 Jul 8. [QxMD MEDLINE Link].
Cohen PR, Prystowsky JH. Pityriasis rubra pilaris: a review of diagnosis and treatment. J Am Acad Dermatol. 1989 May. 20(5 Pt 1):801-7. [QxMD MEDLINE Link].
Magro CM, Crowson AN. The clinical and histomorphological features of pityriasis rubra pilaris. A comparative analysis with psoriasis. J Cutan Pathol. 1997 Aug. 24(7):416-24. [QxMD MEDLINE Link].
Avitan-Hersh E, Bergman R. The Incidence of Acantholysis in Pityriasis Rubra Pilaris-Histopathological Study Using Multiple-Step Sections and Clinicopathologic Correlations. Am J Dermatopathol. 2015 Oct. 37 (10):755-8. [QxMD MEDLINE Link].
Van de Kerkhof PC, Steijlen PM. Topical treatment of pityriasis rubra pilaris with calcipotriol. Br J Dermatol. 1994 May. 130(5):675-8. [QxMD MEDLINE Link].
Karimian-Teherani D, Parissa M, Tanew A. Response of juvenile circumscribed pityriasis rubra pilaris to topical tazarotene treatment. Pediatr Dermatol. 2008 Jan-Feb. 25(1):125-6. [QxMD MEDLINE Link].
Lwin SM, Hsu CK, Liu L, Huang HY, Levell NJ, McGrath JA. Beneficial effect of ustekinumab in familial pityriasis rubra pilaris with a new missense mutation in CARD14. Br J Dermatol. 2017 Mar 16. [QxMD MEDLINE Link].
Feldmeyer L, Mylonas A, Demaria O, Mennella A, Yawalkar N, Laffitte E, et al. Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris. JAMA Dermatol. 2017 Apr 1. 153 (4):304-308. [QxMD MEDLINE Link].
Napolitano M, Abeni D, Didona B. Biologics for pityriasis rubra pilaris treatment: a review of the literature. J Am Acad Dermatol. 2018 Mar 30. [QxMD MEDLINE Link].
Maloney NJ, Hisaw LD, Worswick S. Type I pityriasis rubra pilaris treated with tumor necrosis factor inhibitors, ustekinumab, or secukinumab: a systematic review. J Am Acad Dermatol. 2018 Mar 5. [QxMD MEDLINE Link].
Liang JY, Ye RX, Tian X, Zhang SQ, Zhang XB. Secukinumab monotherapy successfully treated severe refractory type V (atypical juvenile) pityriasis rubra pilaris: A case report and literature review. Dermatol Ther. 2020 Jul 28. e14097. [QxMD MEDLINE Link].
Cook E, Tran KW, Kollipara S, Tarbox M, Akin R. A case of resistant pityriasis ribra pilaris responsive to combination acitrentin and ustekinumab. Dermatol Online J. 2020 Mar 15. 26 (3):[QxMD MEDLINE Link].
Brown F, Badri T. Pityriasis Rubra Pilaris. StatPearls [Internet]. 2020 Jan. [QxMD MEDLINE Link]. [Full Text].
Mellett M. Regulation and dysregulation of CARD14 signalling and its physiological consequences in inflammatory skin disease. Cell Immunol. 2020 Aug. 354:104147. [QxMD MEDLINE Link].
Haynes D, Strunck JL, Topham CA, Ortega-Loayza AG, Kent G, Cassidy PB, et al. Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial. JAMA Dermatol. 2020 Jun 1. 156 (6):668-675. [QxMD MEDLINE Link].
Kohn D, Wetzig T. [Pityriasis rubra pilaris : Successful treatment with ixekizumab]. Hautarzt. 2020 Aug. 71 (8):624-626. [QxMD MEDLINE Link].
Wu KK, Dao H Jr. Off-label dermatologic uses of IL-17 inhibitors. J Dermatolog Treat. 2020 Mar 9. 1-7. [QxMD MEDLINE Link].
Vergilis-Kalner IJ, Mann DJ, Wasserman J, Petronic-Rosic V, Toukas, MM. Pityriasis rubra pilaris sensitive to narrow band-ultraviolet B light therapy. J Drugs Dermatol. 2009. 8:270-273.
Haenssle HA, Bertsch HP, Emmert S, Wolf C, Zutt M. Extracorporeal photochemotherapy for the treatment of exanthematic pityriasis rubra pilaris. Clin Exp Dermatol. 2004 May. 29(3):244-6. [QxMD MEDLINE Link].
Sehgal VN, Srivastava G. (Juvenile) Pityriasis rubra pilaris. Int J Dermatol. 2006 Apr. 45(4):438-46. [QxMD MEDLINE Link].
Dicken CH. Treatment of classic pityriasis rubra pilaris. J Am Acad Dermatol. 1994 Dec. 31(6):997-9. [QxMD MEDLINE Link].
Borok M, Lowe NJ. Pityriasis rubra pilaris. Further observations of systemic retinoid therapy. J Am Acad Dermatol. 1990 May. 22(5 Pt 1):792-5. [QxMD MEDLINE Link].
Garcovich S, Di Giampetruzzi AR, Antonelli G, Garcovich A, Didona B. Treatment of refractory adult-onset pityriasis rubra pilaris with TNF-alpha antagonists: a case series. J Eur Acad Dermatol Venereol. 2010 Aug. 24(8):881-4. [QxMD MEDLINE Link].
Walling HW, Swick BL. Pitryiasis rubra pilaris responding rapidly to adalimumab. Arch Dermatol. 2009. 145:99-101.
Wohlrab J, Kreft B. Treatment of pityriasis rubra pilaris with ustekinumab. Br J Dermatol. 2010 Sep. 163(3):655-6. [QxMD MEDLINE Link].
Eytan O, Sarig O, Sprecher E, van Steensel MA. Clinical response to ustekinumab in familial pityriasis rubra pilaris caused by a novel mutation in CARD14. Br J Dermatol. 2014 Aug. 171(2):420-2. [QxMD MEDLINE Link].
Cox V, Lesesky EB, Garcia BD, O'Grady TC. Treatment of juvenile pityriasis rubra pilaris with etanercept. J Am Acad Dermatol. 2008 Nov. 59(5 Suppl):S113-4. [QxMD MEDLINE Link].
Liao WC, Mutasim DF. Infliximab for the treatment of adult-onset pityriasis rubra pilaris. Arch Dermatol. 2005 Apr. 141(4):423-5. [QxMD MEDLINE Link].
Manoharan S, White S, Gumparthy K. Successful treatment of type I adult-onset pityriasis rubra pilaris with infliximab. Australas J Dermatol. 2006 May. 47(2):124-9. [QxMD MEDLINE Link].
Muller H, Gattringer C, Zelger B, Hopfl R, Eisendle K. Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: case report and review of the literature on biologic therapy. J Am Acad Dermatol. 2008 Nov. 59(5 Suppl):S65-70. [QxMD MEDLINE Link].
Ruiz Villaverde R, Sánchez Cano D. Successful treatment of type 1 pityriasis rubra pilaris with ustekinumab therapy. Eur J Dermatol. 2010 Sep-Oct;. 20(5):630-1.
Clayton BD, Jorizzo JL, Hitchcock MG, et al. Adult pityriasis rubra pilaris: a 10-year case series. J Am Acad Dermatol. 1997 Jun. 36(6 Pt 1):959-64. [QxMD MEDLINE Link].
Wetzig T, Sticherling M. Juvenile pityriasis rubra pilaris: successful treatment with ciclosporin. Br J Dermatol. 2003 Jul. 149(1):202-3. [QxMD MEDLINE Link].
Koch L, Schöffl C, Aberer W, Massone C. Methotrexate Treatment for Pityriasis Rubra Pilaris: A Case Series and Literature Review. Acta Derm Venereol. 2018 Apr 27. 98 (5):501-505. [QxMD MEDLINE Link].
Jancin B. Ixekizumab deemed effective for pityriasis rubra pilaris. MDedge Dermatology. Available at https://www.mdedge.com/dermatology/article/226022/medical-dermatology/ixekizumab-deemed-effective-pityriasis-rubra-pilaris?ecd=wnlpd_new_200728_mdedge_4am&uac=106950CX&utm_source=News%5FMDEDerm%5FeNL%5F072820%5FF&utm_medium=email&utm_content=Ixekizumab%20. July 24, 2020; Accessed: July 28, 2020.